Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to adhere to the prohibitions and restrictions specified in this protocol~* If a woman, must have a negative serum beta human chorionic gonadotropin pregnancy test at screening and a negative urine pregnancy test on Day 1 of Period 1 in Part A and prior to study drug administration in Part B~* Comfortable with self-administration of intranasal medication and able to follow instructions provided~* Normal visual acuity (corrected or uncorrected)~* Based on self-report, able to consume an amount of alcohol that typically produces a blood alcohol concentration (BAC) of 0.05 percent (that is, 2 to 3 alcoholic drinks ingested within 2 hours on a single occasion)~Exclusion Criteria:~* Current or prior diagnosis of psychosis/psychotic or bipolar disorder~* Primary sleep disorder, such as insomnia, requiring pharmacological intervention at Screening~* Clinically significant abnormal values for hematology, clinical chemistry, or urinalysis at screening or Day 1 of Period 1 as deemed appropriate by the investigator~* Clinically significant abnormal physical examination, vital signs, or 12-lead electrocardiogram (ECG) at screening or Day 1 of Period 1 as deemed appropriate by the investigator~* History of moderate or severe use disorder according to Diagnostic and Statistical Manual of Mental Disorders (DSM-IV or DSM-5) criteria within 1 year before screening or positive test result(s) for alcohol and/or drugs of abuse (such as barbiturates, opiates, cocaine, cannabinoids, amphetamines, and benzodiazepines) at screening and Day 1 of Period 1

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Part A: Sequence ABC (Placebo+Alcohol+Esketamine) (Type: EXPERIMENTAL): Participants will receive intranasal placebo on Day 1 and oral placebo on Day 2 \[Treatment A\] in Period 1, then intranasal placebo on Day 1 and Oral alcohol on Day 2 \[Treatment B\] in Period 2, followed by intranasal esketamine on Day 1 and oral placebo on Day 2 \[Treatment C\] in Period 3.
- Part A: Sequence BCA (Placebo+Alcohol+Esketamine) (Type: EXPERIMENTAL): Participants will receive Treatment B in Period 1, then Treatment C in Period 2, followed by Treatment A in Period 3.
- Part A: Sequence CAB (Placebo+Alcohol+Esketamine) (Type: EXPERIMENTAL): Participants will receive Treatment C in Period 1, then Treatment A in Period 2, followed by Treatment B in Period 3.
- Part A: Sequence CBA (Placebo+Alcohol+Esketamine) (Type: EXPERIMENTAL): Participants will receive Treatment C in Period 1, then Treatment B in Period 2, followed by Treatment A in Period 3.
- Part A: Sequence ACB (Placebo+Alcohol+Esketamine) (Type: EXPERIMENTAL): Participants will receive Treatment A in Period 1, then Treatment C in Period 2, followed by Treatment B in Period 3.
- Part A: Sequence BAC (Placebo+Alcohol+Esketamine) (Type: EXPERIMENTAL): Participants will receive Treatment B in Period 1, then Treatment A in Period 2, followed by Treatment C in Period 3.
- Part B: Placebo+Esketamine (Type: EXPERIMENTAL): Participants will receive intranasal placebo on Day 1, followed by intranasal esketamine on Days 4, 8, 11, 15, 18, 22 and 25.

Based on this trial design, predict the completion outcome and termination type (if applicable).